News Stories

Aug, 2017

The National Lipid Association (NLA) welcomes the results of the REVEAL trial which demonstrated that reductions in cholesterol levels with anacetrapib were associated with a reduction in cardiovascular events.  Specifically, cholesterol drug anacetrapib produced reductions in low density lipoprotein (LDL) cholesterol levels, non-high density lipoprotein (non-HDL) cholesterol levels, lipoprotein(a) levels and a profound increase in high density lipoprotein (HDL) cholesterol levels.  These favorable lipid changes were associated with a significant reduction in cardiovascular events

Average: 5 (1 vote)
Name: NLA News
Aug, 2017

The American Board of Clinical Lipidology (ABCL) Board of Directors has published a list of recommended reading for those preparing for maintenance of certification (MOC). If you’re studying for the exam, you can find a list of suggested reading at

Average: 4.5 (2 votes)
Name: NLA News
Jul, 2017

JACKSONVILLE, Fla. – The Foundation of the NLA launched its RADAR (RAre Disease AwarReness) campaign and redesigned website, on Monday.

No votes yet
Name: NLA News

Copyright © 2018 National Lipid Association. All Rights Reserved.

Privacy Policy Terms of Service